Dr. Fong Chan Seng was appointed to the Board as an Independent Non Executive_ Director on 30 May 2019. He is also a member of the Audit Committee, Remuneration Committee and  Nomination Committee.

He graduated with a Degree in Veterinary Science and Animal Husbandry Bombay Veterinary College, India.

Dr. Fong has more than thirty-seven  (37) years of industry  experience.  He held several  job portfolios during his employment with Pfizer – Malaysia. Dr. Fong Joined Pfizer as Veterinary Promotions Manager in 1981 . Throughout seven (7) years of serving the domestic market 1n Malaysia, he held positions as Product Manager, National Sales Manager and FeedmiII Marketing Manager. Dr. Fong was posted to Thailand as the Business Manager of Pfizer Thailand Ltd for three (3) years from 1988 to 1990. His responsibilities included running the animal health business of Pfizer – Thailand, and a premix plant, product formulation, product quality control, and development of product stability.

He was promoted to the position of Regional Director of Sales for Association of South East Asia Nation (“ASEAN”) countries in 1991. He was also in charge of business development for Pfizer in China, Hong Kong and Sri Lanka. When Pfizer acquired the worldwide animal health business of SmithKline Beecham, he was specifically in charge of the acquisition and problem­ solving activities in the Philippines from 1994 to 1996.

In 1998, Dr. Fong together with the existing management of Pfizer in Malaysia, established Sunzen Corporation Sdn. Bhd. (“Sunzen Corporation”) to undertake a management buy-out of Pfizer’s local distribution and marketing operations.

In 2001, Dr. Fong left Sunzen Corporation to join Phibro Animal Health Inc, USA as Regional Director for ASEAN countries and as Managing Director of their local incorporated company, Phibro Malaysia Sdn. Bhd. He rejoined Sunzen Corporation in 2002 and was appointed as an Executive Director of Sunzen Biotech Berhad on 25 April 2008 and subsequently resigned on 18 July 2014.

He does not have any family relationship with any Director and/ or major shareholder of the Company,  nor does  he have  any  conflict  of  interest  with the Company.  He  has  not  been convicted for offences within the past five (5) years other than traffic offences or any public sanction or penalty imposed on him by the relevant regulatory bodies during the financial  year 2021.

He has attended all the eight (8) Board of Directors’ Meetings of the Company held during the financial year ended 31 December 2021.

He does not hold any directorship in other public companies and listed corporations.